Fundraising FoxNeukio
5 known investors
Find your way into Neukio
Sign up to see every warm intro you have to Neukio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neukio team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases. It focuses on innovation in both product and process development to lower cell therapy production costs and expand indication coverage.
Founders & leadership
Investors · 5
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Frequently asked questions
- What does Neukio do?
- Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases. It focuses on innovation in both product and process development to lower cell therapy production costs and expand indication coverage.
- Who founded Neukio?
- Neukio was founded by Liqun Wang.
- Who are Neukio's investors?
- Neukio's investors include Pan-Lin Capital, Alwin Capital, IDG Capital, Lilly Asia Ventures, Sherpa Healthcare Partners.